VYVGART and VYVGART Hytrulo may increase the risk of infection and can cause allergic, infusion or injection-related reactions. The most common side effects of VYVGART and VYVGART Hytrulo are respiratory and urinary tract infections and headache, as well as injection site reactions for VYVGART Hytrulo. See safety data.
*VYVGART for IV infusion and VYVGART Hytrulo for subcutaneous injection are the combined #1 prescribed FDA-approved biologic treatments for adults with anti-AChR antibody positive gMG. Based on IQVIA LAAD from January 2023 to December 2024. Data is based on validated open claims of VYVGART for IV infusion, VYVGART Hytrulo for subcutaneous injection, oral products and other biologics that have been approved by the FDA for the treatment of adults with generalized myasthenia gravis. Patients who had more than one medical claim in this dataset were counted only once, based on a pre-defined hierarchy.
†Defined as a decrease of 2 or more points on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, which measures the severity of 8 common symptoms of gMG, maintained for at least 4 weeks. A lower MG-ADL score means less severe symptoms.
‡Defined as a decrease of 3 or more points on the Quantitative Myasthenia Gravis (QMG) scale, which assesses muscle weakness based on 13 items, maintained for at least 4 weeks. A lower QMG score means less muscle weakness.
§Please see Patient Information. Follow appropriate administration steps and storage and handling guidance in the Instructions for Use.
AChR=acetylcholine receptor.
||Based on published policies from Policy Reporter as of August 2024.
Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
An additional symptom of an allergic reaction with VYVGART HYTRULO can include hives.
These are not all the possible side effects of VYVGART or VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.
Please see full Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection and full Prescribing Information for VYVGART for IV infusion.
VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial. VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.
Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
An additional symptom of an allergic reaction with VYVGART HYTRULO can include hives.
These are not all the possible side effects of VYVGART or VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.
Please see full Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection and full Prescribing Information for VYVGART for IV infusion.
VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial. VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.